May 2, 2013: CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company’s autoRIC™ Device for Chronic Remote Ischemic Conditioning (CRIC). In the DREAM study (Daily REmote Ischemic Conditioning following Acute Myocardial INfarction), a University of Leicester-sponsored Phase II, randomized, placebo-controlled clinical study, CRIC will be evaluated for its ability to prevent negative remodeling of the heart in patients following an acute myocardial infarction. A quarter of patients suffering a heart attack show symptoms of heart failure at the time of admission, and CRIC has the potential to interrupt this disease process. (click to download pdf of full press release)
April 16, 2013: VentriNova, Inc., a cardiac regenerative medicine biotechnology company, announced today that Dr. Hina Chaudhry, Founder, will be presenting VentriNova at the TEDMED 2013 conference April 16-19, 2013 as part of the TEDMED Hive for the most innovative startup companies in healthcare. The meeting takes place at the John F. Kennedy Center for the Performing Arts in Washington, D.C., and it will also be available online at www.TEDMED.com. (click to download pdf of full press release)
March 7, 2013: CellAegis Devices, Inc., announced today that it has received marketing authorization from Health Canada that allows for the commercial introduction in Canada of the Company’s autoRIC™ Device for Remote Ischemic Conditioning (RIC). Health Canada has granted a Medical Device Class III license for use of the autoRIC Device to provide non-invasive RIC for adult patients undergoing cardiothoracic surgery or interventional cardiothoracic procedures, as well as for patients with evolving myocardial infarction. (click to download pdf of full press release)
February 27, 2013: CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company’s autoRICTM Device for Chronic Remote Ischemic Conditioning (CRIC). In a Canadian Institutes of Health Research (CIHR-sponsored Phase II, randomized, double-blind, placebo-controlled, multi-center clinical study, CRIC will be evaluated for its ability to reduce adverse left ventricular remodeling following primary percutaneous coronary intervention (PCI) for St-segment elevation myocardial infarction (STEMI). (click to download pdf of full press release)
February 26, 2013: DecImmune Therapeutics announced today that it has completed a $2.25 million equity financing. The financing is from a new investor Broadview Ventures, along with existing investors Astellas Venture Management and HealthCare Ventures. The new funds will enable rapid advancement toward IND filing for the company’s proprietary antibody therapeutic to reduce tissue damage and improve ventricular function associated with myocardial infarction. (click to download pdf of full press release)